About this trial
The aim of this clinical trial is to compare the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) implantation with standard treatment (diuretic medications, and if necessary, paracenteses) in patients with liver cirrhosis and development of ascites as the first decompensating event.
By creating a shunt between the liver vein and the portal vein, blood is diverted from the portal vein directly into the hepatic vein, which results in a reduction of pressure in the portal vein so that development of ascites is reduced.
Eligibility criteria
Qualifiers
Patients ≥ 18 years and < 80 years
Liver cirrhosis as documented by previous liver biopsy or by a combination of typical clinical, biochemical and sonographic features
Ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites
INR ≤ 1.5
Disqualifiers
Treatment refractory or recurrent ascites at the time of study inclusion
Patients with concomitant variceal bleeding fulfilling the criteria for pre-emptive TIPS implantation (Child-Pugh class C < 14 points or Child-Pugh class B >7 with active bleeding at initial endoscopy or hepatic venous pressure gradient [HVPG] > 20 mmHg at the time of bleeding)
Budd-Chiari syndrome
Portal vein thrombosis (PVT)
Trial design
Treatments tested in this trial
- Transjugular intrahepatic portosystemic shunt (TIPS)
Treatment groups
Sponsors and collaborators
University Hospital Freiburg
Lead sponsor
Jena University Hospital
Collaborator
Johannes Gutenberg University Mainz
Collaborator
University Hospital Muenster
Collaborator
University Hospital, Bonn
Collaborator
University Hospital Munich
Collaborator
Hannover Medical School
Collaborator
University of Leipzig
Collaborator
University Hospital, Aachen
Collaborator
University Hospital Lübeck
Collaborator
Heinrich-Heine University, Duesseldorf
Collaborator